Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.65 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839405 | 1.00 | CHRNA7 (0.65) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3839999 | 0.91 | CHRNA7 (0.67) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3839996 | 0.91 | CHRNA7 (0.67) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3844243 | 0.83 | CHRNA7 (0.60) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3844247 | 0.83 | CHRNA7 (0.60) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3840558 | 0.81 | CHRNA7 (0.61) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3840559 | 0.81 | CHRNA7 (0.61) | CHRNA7LSSCHRM1CHRM2CHRM4 | |
| SCHEMBL3840510 | 0.80 | CHRNA7 (0.75) | CHRNA7LSS | |
| SCHEMBL3842977 | 0.80 | CHRNA7 (0.75) | CHRNA7LSS | |
| Aqw051 SCHEMBL29604108 | 0.79 | CHRNA7 (1.00) | CHRNA7LSSCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-7579362-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2009-08-25 | — | — | US | claimed |